NervGen Pharma Common stock Receivables

NervGen Pharma Common stock (NGEN) currently reports a receivables of $200K as of June 2026. That compares with $97K in the prior-year period — up 105.9% year over year. Use the charts on this page to explore NervGen Pharma Common stock's receivables history and peer comparisons.

NervGen Pharma Common stock's receivables increased from $97K to $200K — a 105.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NervGen Pharma Common stock reported $200K in receivables as of June 2026. That compares with $97K in the prior-year period — up 105.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $200K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NervGen Pharma Common stock, and consider following NGEN for alerts when major investors trade the stock.

NervGen Pharma Common stock is classified in the Healthcare sector. On receivables, it currently shows $200K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NGEN with unrelated industries.